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SUMMARY
This thesis focuses on some analytical and pharmacological aspects of
enantiomers. Enantiomers always exist as a pair of non-identical mirror-images
that resemble each other as a left and a rigbt hand. The confrguration around
the central (carbon) atom is opposite. This remarkable relationship can result
in large differences in biological activity befween the enantiomers
Gbgp!gl!). Often, one enantiomeric form of a compound is preferred by
nature, e.g. L-a'rl.ino acids and D-glucose. The same holds true for various
drugs and other biologically active compounds. In many cases, the intended
effect resides only in one enantiomer, although in general both are applied (in
the racemic drug). Differences can also occur in the disposition of the two
enantiomers in the body Gbp!giL2). Since in most cases the sum of the two
compounds is measured in biofluids, the real pharmacokinetic processes might
be obscured.
However, it is rather troublesome to apply and/or to study both
enantiomers individually, because of the dfficulties of separation for
preparative and bioanalytical purposes. The resemblance between the
enantiomers is high and they can only be separated in an asymmetric
surrounding. A review on appropiate separation techniques, especially
chromatography is given in chapter I.3.
In the work presented here enantiomers of oxyphenonium bromide were
studied. Oryphenonium bromide is a quaternary ammonium compound with
strong anticholinergic properties. It was known that the enantiomers differ
considerably in affinity to the muscarinic receptor. Synthesis, analysis and
pharmacology of the enantiomers of this drug were investigated.
The work described in part II was focused on the synthesis of the
enantiomers of oryphenonium bromide. A preparative separation of the
enantiomers by crystallization of diastereomeric salts was not successful.
Therefore, another approach was used. The acid moiety, cycloherylphenyl-
glycolic acid (CHPGA), could be resolved by crystallization of its
diastereomeric salts with d- and /-ephedrine. After removal of the amine, the
enantiomers of CHPGA were obtained. Enantiomeric purity was assessed with
HPLC and DSC. These acid enantiomers were then esterified with B-chloro-
ethyldiethylamine, followed by methylation with methylbromide, resulting in
enantiomers of oxyphenonium bromide. The pharmaceutical quality was assessed.
Using radioligand bindi"g studies the enantiomers were tested in calf brain
preparations with 3H-NMS as the displaced ligand. The dextro-isomer had a
163
high affiniry to the muscarinic receptor, the eudismic ratio being 38. When,
instead of methylbromide, aaC- or "CJabelled methyliodide was used in the
methylation step, radioactive enantiomers were obtained. The 1aC-labelled
material was used for pharmacokinetic experiments in rats. Carbon-L1 has a
half-life time of 20 minutes and decays under emission of a positron; after
labelling with this isotope oryphenonium could be visualized non-invasively in
the body by Positron Emission Tomography.
When a drug has enantiomeric forms, each should be measurable in the
same sample. For ox5phenonium bromide, resolution was attempted with chiral
HPlC-systems @p!9I__IILD:
- systems with chiral stationary phases, similar to those that were developed
by PirkJe et al.
- a system sontaining d-camphorsulphonic acid as a mobile phase component.
Neither approach was successful, probably due to the relatively large distance
between the chiral centre and the quaternized nitrogen. So far only the
commercially available crr-acid glycoprotein colu-. (EnantioPacR) could resolve
racemic oryphenoniu- bromide. However, efficiency and stability were
insufficient for bioanalytical applications.
Therefore, it was tried to resolve the enantiomers of CHPGA, the acid
part of the anticholinergic drug @hqplqJIIZ and III.3). An HPLC system
having B-cyclodextrin as the chiral stationary phase was developed. Using
aqueous mobile phases, CHPGA and a number of other aromatic carborylic
acids could be resolved. The influence of temperature and sample concentration
on selectivity and resolution was taken into consideration, but difficulties in
quantitative analysis were encountered. Later on, an opportunity arose to
compare the home-made column with a commercially available B-cyclodextrin
column. The latter showed better separation characteristics for CHPGA. In
addition, a reversed elution order of the enantiomers was seen with the two
columns. Enantiomeric impurities of d- and /-CHPGA were determined as being
0.1 and 0.4 Vo, respectively.
The differences in atrinity of oxyphenonium enantiomers to muscariuic
receptors was found to be considerable. The aim of the studies described in
pait IV was to investigate whether the stereochemical differences also result
in unequal pharmacokinetics of the enantiomers. The study was performed in
the intact rat and in the isolated perfused rat liver using 'oC-labelled
material.
In the intact rat the bile duct, urine bladder and carotid artery were
ca"nulated and the lumen of the small intestine was perfused. The radioactivity
L64
in the body fluids was measured during 90 minutes after a bolus injection of
d- or /-oryphenonium. For d-oryphenonium the total excretion of radioactivity
in bile was considerable higher than for /-oxyphenonium. However, differences
in kinetics were partly obscured by the pharmacodynamic effects of the
eutomer, especially after relatively high doses.
In the isolated perfused rat liver, in accordance with the in vivo results,
the biliary excretion was significantly larger for the deKro- than for the
levo-isomer. Hepatic uptake rate was 5imilss, but total biliary excretion of the
levo-isomer was only 55 Vo compared to the excretion of the dextro-isomer. In
line with these data, after 2 hours only 30 Vo of the dose of the dextro-isomer
and over 50 Vo of. the dose of the levo-isomer was still fouud in the liver.
The metabolic profile was investigated using ion pair TLC. In urine only
the parent compound was found. In contrast, at least two metabolites were
detected in bile for both enantiomers. However, unchanged /-oryphenonium
persisted for a longer period at low levels in bile, indicating either a more
rapid canalicular transport oi the deKro-isomer and/or a more rapid
metabolism of d-oryphenonium to cholephilic metabolites.
In part V two clinical experiments are described. In the first, performed
in 8 healthy volunteers, an intramuscular dose of L mg d- or /-oxyphenonium
bromide was applied in a double-blind cross-over design. Heart rate was
observed for 6 hours and urinary excretion f.or 24 hours. Whereas d-
oryphenonium gave a significant increase of the heart rate for at least 3
hours, no significant effect was measured when /-oryphenonium was applied. In
6 out of the 8 volunteers more d- tban /-oryphenonium was excreted in urine.
Unfortunately, so far no plasma concentrations could be measured, which is
necessary for a better understanding of the observed differences in urinary
excretion between the enantiomers.
In a second study racemic oryphenonium bromide, its enantiomers and a
placebo were inhaled by eight adult patients with chronic airflow obstruction
in a four-way double-blind cross-over study. Forced expiratory volume in one
second (FEVa) and slow inspiratory vital capacity (VC) were measured during
the first 6 hours 3f1s1 inhslstion. d-Oryphenonium was found to be the active
isomer, providing better bronchodilation than racemic oxyphenonium. The effect
of the distomer on FEV' and VC was not significantly different from placebo.
The availability of the enantiomers of oryphenonium bromide give novel
possibilities for the study of muscarinic receptors, of metabolic enryme systems
and of carriers in transport processes of quaternary ammonium compounds.
